Shree Pacetronix Ltd
₹ 79.5
-5.29%
13 Jun
- close price
About
Incorporated in 1988, Shree Pacetronix Ltd manufactures and exports Implantable Cardiac Pacemakers.
Key Points
- Market Cap ₹ 28.6 Cr.
- Current Price ₹ 79.5
- High / Low ₹ 245 / 61.1
- Stock P/E 38.1
- Book Value ₹ 38.3
- Dividend Yield 0.00 %
- ROCE 8.96 %
- ROE 5.59 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 24.2%
- Debtor days have increased from 102 to 144 days.
- Working capital days have increased from 173 days to 259 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 6.89 | 7.44 | 6.94 | 6.80 | 7.28 | 8.77 | 7.56 | 9.23 | 20.26 | 22.04 | 16.80 | |
| 6.60 | 5.86 | 6.37 | 6.39 | 5.88 | 6.50 | 7.57 | 6.62 | 7.45 | 14.81 | 16.16 | 14.49 | |
| Operating Profit | 1.40 | 1.03 | 1.07 | 0.55 | 0.92 | 0.78 | 1.20 | 0.94 | 1.78 | 5.45 | 5.88 | 2.31 |
| OPM % | 17.50% | 14.95% | 14.38% | 7.93% | 13.53% | 10.71% | 13.68% | 12.43% | 19.28% | 26.90% | 26.68% | 13.75% |
| 0.01 | 0.03 | 0.02 | 0.05 | 0.01 | 0.17 | 0.04 | 0.05 | 0.07 | 0.10 | 0.14 | 0.12 | |
| Interest | 0.47 | 0.42 | 0.37 | 0.40 | 0.32 | 0.32 | 0.38 | 0.35 | 0.29 | 0.30 | 0.45 | 0.58 |
| Depreciation | 0.60 | 0.76 | 0.77 | 0.65 | 0.42 | 0.38 | 0.51 | 0.51 | 0.50 | 0.63 | 0.95 | 0.81 |
| Profit before tax | 0.34 | -0.12 | -0.05 | -0.45 | 0.19 | 0.25 | 0.35 | 0.13 | 1.06 | 4.62 | 4.62 | 1.04 |
| Tax % | 32.35% | -58.33% | 60.00% | -26.67% | 31.58% | 44.00% | 31.43% | 61.54% | 26.42% | 29.44% | 27.49% | 27.88% |
| 0.23 | -0.06 | -0.09 | -0.32 | 0.13 | 0.14 | 0.24 | 0.05 | 0.78 | 3.26 | 3.36 | 0.75 | |
| EPS in Rs | 0.64 | -0.17 | -0.25 | -0.89 | 0.36 | 0.39 | 0.67 | 0.14 | 2.17 | 9.06 | 9.33 | 2.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 14% |
| 3 Years: | 22% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 27% |
| 3 Years: | 0% |
| TTM: | -78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 48% |
| 3 Years: | 60% |
| 1 Year: | -63% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 |
| Reserves | 1.86 | 1.77 | 1.68 | 1.36 | 1.60 | 1.74 | 1.98 | 2.03 | 2.81 | 6.07 | 9.43 | 10.18 |
| 2.14 | 2.78 | 1.97 | 2.71 | 2.93 | 3.91 | 3.33 | 3.20 | 3.05 | 2.19 | 4.30 | 5.07 | |
| 1.38 | 0.95 | 1.35 | 1.16 | 1.33 | 1.35 | 2.08 | 2.15 | 2.72 | 4.68 | 4.42 | 4.20 | |
| Total Liabilities | 8.98 | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 23.05 |
| 3.42 | 3.13 | 2.55 | 2.02 | 1.88 | 2.40 | 2.47 | 2.69 | 2.56 | 3.12 | 4.24 | 3.87 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.77 | 0.99 | 1.25 | 1.81 | 1.64 | 1.65 | 1.66 | 0.93 | 0.93 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5.56 | 5.97 | 6.05 | 6.04 | 6.59 | 6.95 | 6.71 | 6.65 | 7.97 | 11.76 | 16.58 | 18.25 | |
| Total Assets | 8.98 | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 23.05 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.06 | 0.47 | 1.35 | 0.42 | 1.13 | 0.31 | 2.25 | 1.09 | 1.76 | 1.69 | -0.04 | -0.01 | |
| -0.44 | -0.49 | -0.18 | -0.86 | -0.52 | -1.01 | -1.00 | -0.53 | -1.19 | -1.41 | -1.67 | -0.04 | |
| -0.85 | 0.20 | -1.14 | 0.22 | -0.50 | 0.36 | -1.17 | -0.31 | -0.45 | -1.10 | 1.75 | 0.19 | |
| Net Cash Flow | -0.23 | 0.18 | 0.03 | -0.22 | 0.10 | -0.34 | 0.08 | 0.25 | 0.12 | -0.82 | 0.04 | 0.14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86.23 | 70.99 | 88.31 | 113.08 | 143.32 | 152.92 | 134.01 | 145.81 | 127.73 | 84.85 | 77.17 | 144.04 |
| Inventory Days | 443.76 | 670.58 | 359.32 | 243.33 | 301.93 | 276.44 | 216.62 | 272.02 | 194.20 | 157.41 | 285.83 | 463.17 |
| Days Payable | 48.46 | 29.71 | 32.67 | 18.86 | 49.65 | 37.10 | 54.15 | 48.57 | 17.55 | 32.22 | 12.45 | 57.32 |
| Cash Conversion Cycle | 481.52 | 711.86 | 414.96 | 337.55 | 395.60 | 392.26 | 296.48 | 369.25 | 304.38 | 210.04 | 350.55 | 549.89 |
| Working Capital Days | 179.31 | 235.74 | 197.71 | 216.69 | 209.34 | 217.09 | 129.44 | 159.33 | 120.22 | 96.02 | 163.79 | 258.98 |
| ROCE % | 10.53% | 3.56% | 4.16% | -0.80% | 6.46% | 5.06% | 7.93% | 5.30% | 14.43% | 46.15% | 34.74% | 8.96% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Dear Sir/Madam, Kindly find enclosed herewith the extracts of Newspaper Publication Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015 of the Audited Standalone and …
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 30.05.2025
30 May - Approved FY25 audited results with modified opinion; appointed new auditors and company secretary.
-
Submission Of Audited Financial Results (Standalone And Consolidated) Along With Audit Report For The Quarter And Financial Year Ended 31St March 2025.
30 May - Audited FY25 results with qualified opinion due to suspended subsidiary project investment impairment risk.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Appointed secretarial auditor for 5 years, internal auditor for FY 2025-26; company secretary resigned and new appointed.
-
Board Meeting Intimation for Intimation Of Board Meeting (01St/2025-2026) Of The Company.
21 May - Board meeting on May 30 to approve FY25 audited financial results; trading window closed Apr 1-Jun 1.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1][2]
Company deals in 3 major products viz, Pacemakers, Pacing Leads, Pacing System which are further bifurcated as: Ventralite 940+/ Tiranga, Pinnacle-8820, Tiranga -302, Pinnacle-R-SSIR-Model-29, Trinity-R, Smart - E, Atrial-J-Bipolar-Lead-3851-VB, Introducer, Zeus -1, Is1 Bipolar Lead 3851 Vb, Screw-in Lead P12, Pace Maker Analyser, Charak DDDR, Indus I SSB, Implantable Cardioverter Pacemaker, Single Chamber Pacemaker, Reuters Pacemakers, Permanent Pacemaker, Medtronic Pacemaker, Pacing System Analyzer